Rational Combinations of Targeted Cancer Therapies: Background, Advances and Challenges

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2022 Dec 12

PMID 36509911

Authors

Haojie Jin

Liqin Wang

Rene Bernards

Affiliations

Soon will be listed here.

Abstract

Over the past two decades, elucidation of the genetic defects that underlie cancer has resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be highly effective, resistance to single-agent therapies remains a major challenge. Combining drugs can help avoid resistance, but the number of possible drug combinations vastly exceeds what can be tested clinically, both financially and in terms of patient availability. Rational drug combinations based on a deep understanding of the underlying molecular mechanisms associated with therapy resistance are potentially powerful in the treatment of cancer. Here, we discuss the mechanisms of resistance to targeted therapies and how effective drug combinations can be identified to combat resistance. The challenges in clinically developing these combinations and future perspectives are considered.

Citing Articles

A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy.

Zhang S, Wu N, Geng Y, Guan L, Niu M, Li J Front Pharmacol. 2025; 16:1560559.

PMID: 40078291 PMC: 11897524. DOI: 10.3389/fphar.2025.1560559.

Design, Synthesis, and Cytotoxicity Evaluation of Novel Indolin-2-One Based Molecules on Hepatocellular Carcinoma HepG2 Cells as Protein Kinase Inhibitors.

Kandeel M, AbdElhameid M, Adel M, Al-Shorbagy M, Negmeldin A Molecules. 2025; 30(5).

PMID: 40076329 PMC: 11901902. DOI: 10.3390/molecules30051105.

Hallmarks of artificial intelligence contributions to precision oncology.

Chang T, Park S, Schaffer A, Jiang P, Ruppin E Nat Cancer. 2025; .

PMID: 40055572 DOI: 10.1038/s43018-025-00917-2.

Versatile Nanomaterials That Interfere with Ferroptosis in the Tumor Microenvironment.

Liu Y, Liu Y, Li X, Li S, Zhang X, Si L Int J Nanomedicine. 2025; 20:2461-2473.

PMID: 40027870 PMC: 11871933. DOI: 10.2147/IJN.S508767.

Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4 mediated PKM2 nuclear translocation.

He R, Hu C, Yuan Y, Li T, Tian Q, Huang T Cell Death Dis. 2025; 16(1):126.

PMID: 39988592 PMC: 11847919. DOI: 10.1038/s41419-025-07431-4.

References

Goodman L, Wintrobe M . Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 2010; 132:126-32. DOI: 10.1001/jama.1946.02870380008004. View

Frei 3rd E, HOLLAND J, Schneiderman M, Pinkel D, SELKIRK G, Freireich E . A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958; 13(12):1126-48. View

Shafer R, Vuitton D . Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother. 1999; 53(2):73-86. DOI: 10.1016/s0753-3322(99)80063-8. View

Dentro S, Leshchiner I, Haase K, Tarabichi M, Wintersinger J, Deshwar A . Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell. 2021; 184(8):2239-2254.e39. PMC: 8054914. DOI: 10.1016/j.cell.2021.03.009. View

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

Wong S, Witte O . The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004; 22:247-306. DOI: 10.1146/annurev.immunol.22.012703.104753. View

Haslam A, Kim M, Prasad V . Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. Ann Oncol. 2021; 32(7):926-932. DOI: 10.1016/j.annonc.2021.04.003. View

Rotow J, Bivona T . Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017; 17(11):637-658. DOI: 10.1038/nrc.2017.84. View

Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K . Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012; 11(11):873-86. DOI: 10.1038/nrd3847. View

10.

Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D . The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019; 575(7781):217-223. DOI: 10.1038/s41586-019-1694-1. View

11.

Hartwell L, Szankasi P, Roberts C, Murray A, Friend S . Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997; 278(5340):1064-8. DOI: 10.1126/science.278.5340.1064. View

12.

Kaelin Jr W . The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005; 5(9):689-98. DOI: 10.1038/nrc1691. View

13.

Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View

14.

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

15.

Lyu J, Yang E, Zhang B, Wu C, Pardeshi L, Shi C . Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics. Nat Commun. 2020; 11(1):5105. PMC: 7547687. DOI: 10.1038/s41467-020-18872-0. View

16.

Thompson J, Nguyen Q, Singh M, Pavesic M, Nesterenko I, Nelson L . Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Oncogene. 2016; 36(8):1080-1089. PMC: 5323317. DOI: 10.1038/onc.2016.272. View

17.

Hu L, Xie H, Liu X, Potjewyd F, James L, Wilkerson E . TBK1 Is a Synthetic Lethal Target in Cancer with Loss. Cancer Discov. 2019; 10(3):460-475. PMC: 7058506. DOI: 10.1158/2159-8290.CD-19-0837. View

18.

Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J . Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature. 2017; 542(7642):484-488. PMC: 5448706. DOI: 10.1038/nature21357. View

19.

Zhao D, Cai L, Lu X, Liang X, Li J, Chen P . Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. Cancer Discov. 2020; 10(9):1374-1387. PMC: 7483306. DOI: 10.1158/2159-8290.CD-19-1352. View

20.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View